Print Clear

Prior Authorization Request Administrative Information

Member information

Last name _____ First name _____ MI _____

Member ID _____ Date of birth _____

Sex assigned at birth ☐ Female ☐ Male ☐ "X" or Intersex

Current gender ☐ Female ☐ Male ☐ Transgender male ☐ Transgender female ☐ Other _____

Place of residence ☐ Home ☐ Nursing facility ☐ Other _____

Race _____ Ethnicity _____

Preferred spoken language _____ Preferred written language _____

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

Plan contact information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan
☐ **MassHealth Drug Utilization Review Program** Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)
☐ **Fallon Health** Online Prior Authorization: go.covermymeds.com/OptumRx Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033
☐ **Health New England** Online Prior Authorization: go.covermymeds.com/OptumRx Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545
☐ **Mass General Brigham Health Plan** Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555
☐ **Tufts Health Plan** Online Prior Authorization: point32health.promptpa.com Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985
☐ **WellSense Health Plan** Online Prior Authorization: wellsense.org/providers/ma/pharmacy/prior-authorizations Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

over

Anticonvulsant
Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about anticonvulsants and the **Pediatric Behavioral Health Medication Initiative**, including PA requirements, a complete list of all behavioral health medications, and preferred products, can be found within the MassHealth Drug List at **www.mass.gov/druglist**. The related PA form is available at: **Pediatric Behavioral Health Medication Initiative PA Request Form**.

Medication information

Medication requested (Check one or all that apply.)

- ☐ Aptiom (eslicarbazepine)
- ☐ Briviact (brivaracetam solution, tablet)
- ☐ Diacomit (stiripentol)
- ☐ diazepam rectal gel > 5 kits (10 syringes)/30 days
- ☐ Elepsia XR (levetiracetam extended-release)
- ☐ Epidiolex (cannabidiol)
- ☐ Eprontia (topiramate solution)
- ☐ everolimus 2.5 mg, 5 mg, 7.5 mg, 10 mg
- ☐ everolimus tablets for oral suspension
- ☐ Fintepla (fenfluramine)
- ☐ Fycompa (perampanel)
- ☐ gabapentin >3600 mg/day
- ☐ Lamictal XR starter kit, lamotrigine extended-release
- ☐ lamotrigine orally disintegrating tablet (ODT), ODT starter kit
- ☐ lamotrigine tablet starter kit
- ☐ Libervant (diazepam buccal film) > 10 units/30 days or ≥ 6 years of age
- ☐ Motpoly XR (lacosamide extended-release capsule)
- ☐ Nayzilam (midazolam nasal spray) >10 units/30 days
- ☐ oxcarbazepine extended-release
- ☐ pregabalin > 600 mg/day
- ☐ rufinamide
- ☐ Spritam (levetiracetam tablet for oral suspension)
- ☐ Sympazan (clobazam film)
- ☐ tiagabine
- ☐ topiramate extended-release capsule [Trokendi XR]
- ☐ Valtoco (diazepam nasal spray) >10 units/30 days
- ☐ vigabatrin powder packet, tablet
- ☐ Vigafyde (vigabatrin solution)
- ☐ Xcopri (cenobamate)
- ☐ Zonisade (zonisamide suspension)
- ☐ Ztalmy (ganaxolone)
- ☐ Other*

Dose, frequency, and duration of medication requested

Drug NDC (if known) or service code

** If request is for a non-preferred brand name or generic product, please attach supporting documentation (e.g., copies of medical records and/or office notes regarding adverse reaction or inadequate response to the preferred product).*

Indication (Check all that apply or include ICD-10 code, if applicable.)

- ☐ Bipolar disorder
- ☐ Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) (provide documentation of genetic testing)
- ☐ Diabetic peripheral neuropathy
- ☐ Dravet syndrome
- ☐ Epilepsy or seizure disorder
  Type
- ☐ Epilepsy associated with tuberous sclerosis complex
- ☐ Fibromyalgia
- ☐ Infantile spasms
- ☐ Lennox-Gastaut syndrome
- ☐ Migraine prophylaxis
- ☐ Pain associated with trigeminal neuralgia
- ☐ Postherpetic neuralgia
- ☐ Other

Please list all other medications currently prescribed for the member for this indication.

Please indicate prescriber specialty below.

☐ Neurology ☐ Psychiatry ☐ Other

If prescriber is not a specialist, please attach consult notes from specialist.

For mid-level practitioners (e.g., nurse practitioners, physician assistants), please provide the name and specialty of the collaborating physician, if applicable.

Is this member a referral candidate for care coordination? ☐ Yes ☐ No

If yes, MassHealth will offer care coordination services to this member. Please describe which additional behavioral health services would be beneficial. *Please inform the member, parent, or legal guardian to expect outreach from a MassHealth representative of care coordination services.*

Section I. Please complete for all requests as needed.

Please provide the following information regarding previous trials.*

1. Drug Dates of Use Outcome
2. Drug Dates of Use Outcome
3. Drug Dates of Use Outcome
4. Drug Dates of Use Outcome

**Attach a letter with additional information regarding medication trials as applicable.*

Section II. Please also complete for requests for Elepsia XR, Eprontia, Lamictal XR starter kit, lamotrigine extended-release, lamotrigine tablet starter kit, Motpoly XR, oxcarbazepine extended-release, Spritam, topiramate extended-release capsule [Trokendi XR], Vigafyde, and Zonisade.

Please provide medical necessity for the use of the requested formulation instead of the respective formulation(s) that is available without prior authorization. For Motpoly XR and Vigafyde, please also provide the member's current weight.

Section III. Please complete for requests for gabapentin containing agents > 3600 mg/day and pregabalin containing agents > 600 mg/day.

Please provide clinical rationale for exceeding the maximum daily dose limit.

over

Section IV. Please complete for requests for Diacomit.

1. Has the member experienced an inadequate response or adverse reaction to other anticonvulsants?
   ☐ Yes. Please complete Section I above.
   ☐ No. Explain why other anticonvulsants have not been tried.
2. Will the requested agent be used in combination with clobazam? ☐ Yes ☐ No

Section V. For requests for Epidiolex, please attach medical records supporting the diagnosis.

Section VI. Please complete for requests for lamotrigine ODT.

1. Does the member have a medical condition in which they are not able to swallow pills?
   ☐ Yes. Please describe. ☐ No
2. Has the member experienced an inadequate response or adverse reaction to lamotrigine dispersible tablets?
   ☐ Yes. Please describe trial below.
   Dose and frequency Dates of Use Outcome
   ☐ No. Explain why lamotrigine dispersible tablets have not been tried.

Section VII. Please complete for requests for diazepam rectal gel (> 5 kits/month), Libervant (> 10 units/30 days), Nayzilam (> 10 units/30 days), and Valtoco (> 10 units/30 days).

1. Is the diagnosis for as needed (intermittent) treatment of acute seizure clusters that are distinct from a member's usual seizure pattern? ☐ Yes ☐ No
2. Please describe the medical necessity for use over quantity limits.

Section VIII. Please complete for requests for Libervant for members ≥ six years of age.

1. Is the diagnosis for as needed (intermittent) treatment of acute seizure clusters that are distinct from a member's usual seizure pattern? ☐ Yes ☐ No
2. Has the member experienced an inadequate response or adverse reaction to Valtoco?
   ☐ Yes. Please describe trial below.
   Dose and frequency Dates of Use Outcome
   ☐ No. Explain why Valtoco has not been tried.

Section IX. Concomitant gabapentin and pregabalin for all formulations. Complete this section for all members, if request will result in prescription of concomitant gabapentin and pregabalin.

Please document complete treatment plan.

1. gabapentin dose/frequency Indication
2. pregabalin dose/frequency Indication
3. Other(s)

over

Please document clinical rationale for concomitant use of gabapentin and pregabalin for this member.

Please document monotherapy trials (include dose/frequency, dates/duration of use, and outcome) with gabapentin and pregabalin.*

Has the member experienced an inadequate response or adverse reaction to at least two other alternative agents for the requested indication(s)?

☐ Yes. Please complete Section I above.

☐ No. Explain why other alternative agents have not been tried.

Section X. Please complete and provide documentation for exceptions to step therapy.

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to, the member? ☐ Yes ☐ No
   If yes, briefly describe details of contraindication, adverse reaction, or harm.

2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?
   ☐ Yes ☐ No
   If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.

3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?
   ☐ Yes ☐ No
   If yes, please provide details for the previous trial.
   Drug name Dates/duration of use
   Did the member experience any of the following? ☐ Adverse reaction ☐ Inadequate response
   Briefly describe details of adverse reaction or inadequate response.

4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in, or physical or mental harm to, the member?
   ☐ Yes. Please provide details.
   ☐ No

**Attach a letter with additional information regarding medication trials as applicable.*

over

MassHealth Pediatric Behavioral Health Medication Initiative

Please fill out all the sections below, as applicable, for pediatric members only. You may also use the Pediatric Behavioral Health Medication Initiative PA Request Form if the member is prescribed other behavioral health medications.

Section I. Please complete for all requests for medications subject to the Pediatric Behavioral Health Medication Initiative for members < 18 years of age.

Please document complete treatment plan listing all requested agents (include all behavioral health agents, corresponding strength, dose, directions of use and indication(s) or ICD-10 code(s), if applicable, for each medication(s)).

1. Medication name _____ Dose/frequency _____ Indication _____
2. Medication name _____ Dose/frequency _____ Indication _____
3. Medication name _____ Dose/frequency _____ Indication _____
4. Medication name _____ Dose/frequency _____ Indication _____
5. Medication name _____ Dose/frequency _____ Indication _____
6. Medication name _____ Dose/frequency _____ Indication _____
7. Other(s) _____

Is the member currently in an acute care setting?

☐ Yes (Inpatient) ☐ Yes (Community Based Acute Treatment)
☐ Yes (Partial Hospitalization) ☐ No

For members who are in an acute care setting, please document the outpatient prescriber after discharge.

Prescriber name _____ Contact information _____

Has the member been hospitalized for a psychiatric condition within the past three months?

☐ Yes. Please document dates of hospitalization within the past three months. _____
☐ No

On the current regimen, is the member considered to be a severe risk of harm to self or others?

☐ Yes. Please provide details. _____ ☐ No

For regimens including an antipsychotic, are appropriate safety screenings and monitoring being conducted (e.g., weight, metabolic, movement disorder, cardiovascular, and prolactin-related effects)?

☐ Yes ☐ No. Please explain. _____

Has informed consent from a parent or legal guardian been obtained?* ☐ Yes ☐ No

Please indicate prescriber specialty below.

☐ Psychiatry ☐ Neurology ☐ Other _____
☐ Specialist consult details (if the prescriber submitting the request is not a specialist)

_____

Name(s) of the specialist(s) _____ Date(s) of last visit or consult _____

Contact information _____

over

For mid-level practitioners (e.g., nurse practitioners, physician assistants), please provide the name and specialty of the collaborating physician, if applicable.

Please document member custody status.

☐ Parent/Guardian ☐ Department of Children and Families (DCF)

Please document member placement status.

☐ Home with Parent/Guardian ☐ Foster Care ☐ Residential Treatment Facility

☐ Uncertain ☐ Other

Please document agency involvement.

☐ DCF ☐ Department of Mental Health (DMH) ☐ Department of Developmental Services (DDS)

☐ Department of Youth Services (DYS)

Is the member/family currently receiving appropriate psychotherapeutic and/or community based services for the targeted clinical mental health related concerns (e.g., Applied Behavioral Analysis, Children's Behavioral Health Initiative, school interventions, specialized placement)?

☐ Yes. Please document details of interventions below, if applicable. ☐ No

Psychiatric care provided is coordinated with other psychotherapeutic and community based services. ☐ Yes ☐ No

** Sample informed consent form available on the MassHealth PBHMI Information webpage. For additional information go to: https://www.mass.gov/info-details/pediatric-behavioral-health-medication-initiative-pbhmi-information*

Please complete for members who have been on one of the following for the past 12 months with no adjustments (i.e., dose decrease, attempted discontinuation): a polypharmacy regimen, members < six years of age who have been on an applicable behavioral health medication, and members < ten years of age who have been on an antipsychotic.

Have previous efforts to reduce or simplify the regimen in the past 24 months resulted in symptom exacerbation? ☐ Yes ☐ No

The family or caregiver does not support the regimen change at this time due to risk of exacerbation.

☐ Yes ☐ No

Is there another significant barrier for therapy discontinuation? ☐ Yes ☐ No

If yes, please explain.

Section II. Mood Stabilizer Polypharmacy. Complete this section for all members < 18 years of age, if request will result in prescription of three or more mood stabilizers for ≥ 60 days within a 90-day period (agents considered to be used only for seizure diagnoses are not included).

Please document if monotherapy trials (include drug name, dates/duration of use, and outcome) with mood stabilizers were tried before prescribing polypharmacy with three or more mood stabilizers in this member.*

Please document the treatment plans for medication regimen simplification (e.g., dose consolidation, frequency reduction) or medical necessity for continuation of a complex medication regimen.

over

Has the member been on a mood stabilizer polypharmacy regimen for the past 12 months with no adjustments (i.e., dose decrease, attempted discontinuation)?
☐ Yes. Please complete the applicable question in Section I. ☐ No

**Attach a letter with additional information regarding medication trials as applicable.*

Section III. Mood Stabilizer Request for Members < six years of age (agents considered to be used only for seizure diagnoses are not included).

Please document any previous medication trial(s). Include the drug name, dates/duration of use, and outcome.*

Please document clinical rationale for use of a mood stabilizer for this member < six years of age.

Has the member been on the requested agent for the past 12 months with no adjustments (i.e., dose decrease, attempted discontinuation)? ☐ Yes. Please complete the applicable question in Section I. ☐ No

**Attach a letter with additional information regarding medication trials as applicable.*

Section IV. Multiple Behavioral Health Medications.

Complete this section for all members < 18 years of age if request will result in prescriptions of four or more behavioral health medications within a 45-day period if one of the following is included: an antipsychotic, a benzodiazepine, divalproex/valproate, lithium, or a tricyclic antidepressant.

Also complete this section for all members < 18 years of age if request will result in prescriptions of five or more behavioral health medications within a 45-day period. For a complete list of all behavioral health medications, please refer to the MassHealth Pediatric Behavioral Health Medication Initiative.

Please document monotherapy trials (include drug name, dates/duration of use, and outcome) tried before prescribing a polypharmacy regimen for this member.*

Please document the treatment plans for medication regimen simplification (e.g., dose consolidation, frequency reduction) or medical necessity for continuation of a complex medication regimen

Has the member been on the requested polypharmacy regimen for the past 12 months with no adjustments (i.e., dose decrease, attempted discontinuation)? ☐ Yes. Please complete the applicable question in Section I. ☐ No

**Attach a letter with additional information regarding medication trials as applicable.*

Please continue to next page and complete Prescriber and Provider Information section.

over

Prior Authorization Request Prescriber and Provider Information

Prescriber information

Last name* First name* MI

NPI* Individual MH Provider ID

DEA No. Office Contact Name

Address City State Zip

E-mail address

Telephone No.*

Fax No.* (Please provide fax number for PA response notification.)

** Required*

Please also complete for professionally administered medications, if applicable.

Start date End date

Servicing prescriber/facility name ☐ Same as prescribing provider

Servicing provider/facility address

Servicing provider NPI/tax ID No.

Name of billing provider

Billing provider NPI No.

Is this a request for recertification? ☐ Yes ☐ No

CPT code No. of visits J code No. of units

Provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am either the prescribing provider or duly authorized to act on behalf of the provider identified in the Prescriber information section of this form. Any attached statement on letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Signature of provider or individual duly authorized to act on behalf of the provider:

Printed legal name and title of signatory above

Date

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)